Gynaecomastia in males can have various underlying causes, some of which may be serious, such as endocrine disorders, liver failure, kidney failure, or malignancy. Additionally, medication-related causes should be considered, as in the case of this patient who was taking finasteride, which is known to cause gynaecomastia. Finasteride functions by inhibiting 5-alpha-reductase, which reduces dihydrotestosterone production and shrinks the prostate. However, it can also lead to side effects such as sexual dysfunction and gynaecomastia.

Understanding Finasteride: Its Uses and Side Effects

Finasteride is a medication that works by inhibiting the activity of 5 alpha-reductase, an enzyme responsible for converting testosterone into dihydrotestosterone. This drug is commonly used to treat benign prostatic hyperplasia and male-pattern baldness.

However, like any medication, finasteride has its own set of adverse effects. Some of the most common side effects include impotence, decreased libido, ejaculation disorders, gynaecomastia, and breast tenderness. It is important to note that finasteride can also cause decreased levels of serum prostate-specific antigen.

Differential Diagnosis for Hypercalcaemia with Elevated PTH Levels

Hypercalcaemia with elevated parathyroid hormone (PTH) levels can be indicative of several conditions. Here are some possible differential diagnoses:

Multiple Endocrine Neoplasia Type 2A (MEN 2A)
MEN 2A is caused by a gain in function mutation in the RET proto-oncogene. The classic triad of MEN 2A is medullary thyroid carcinoma, primary hyperparathyroidism, and phaeochromocytoma. Patients with MEN 2A may also have treatment-resistant hypertension.

Marfan Syndrome
Marfan syndrome is a hereditary disorder of connective tissue. Patients with Marfan syndrome are typically tall and thin with hyperlax joints, recurrent dislocation of the lens of the eye, and cardiovascular anomalies (particularly aortic regurgitation). However, dysfunction of the parathyroid hormone axis is not usually associated with this condition.

Multiple Endocrine Neoplasia Type 1 (MEN 1)
MEN 1 also occurs due to a mutation in the RET gene. However, patients with MEN 1 classically suffer from hyperparathyroidism, pituitary adenomas (typically prolactinomas), and pancreatic islet cell tumors, and not the features described in the case.

Multiple Myeloma
Multiple myeloma is also associated with hypercalcaemia, but PTH levels would be appropriately low.

Neurofibromatosis
Neurofibromatosis is a disorder caused by a mutation in the neurofibromin gene on chromosome 17. It is associated with multiple neural tumors together with a variety of skin, musculoskeletal, and ocular manifestations, but disruption of the parathyroid hormone axis is not a feature.

Phenytoin: Mechanism of Action and Adverse Effects

Phenytoin is a medication used to manage seizures. Its mechanism of action involves binding to sodium channels, which increases their refractory period. However, the drug is associated with a large number of adverse effects, which can be categorized as acute, chronic, idiosyncratic, and teratogenic. Acute effects include dizziness, diplopia, nystagmus, slurred speech, ataxia, confusion, and seizures. Chronic effects include gingival hyperplasia, hirsutism, coarsening of facial features, drowsiness, megaloblastic anemia, peripheral neuropathy, enhanced vitamin D metabolism causing osteomalacia, lymphadenopathy, and dyskinesia. Idiosyncratic effects include fever, rashes, hepatitis, Dupuytren’s contracture, aplastic anemia, and drug-induced lupus. Teratogenic effects are associated with cleft palate and congenital heart disease. Although routine monitoring of phenytoin levels is not necessary, trough levels should be checked before dosing in cases of dose adjustment, suspected toxicity, or non-adherence to the prescribed medication.

It is important to inform patients about the possibility of developing subconjunctival haemorrhage after receiving intravitreal injections, as it is a common iatrogenic complication. This condition causes a red eye but is not painful and typically resolves within a couple of weeks.

Understanding Subconjunctival Haemorrhage

Subconjunctival haemorrhage occurs when blood vessels bleed into the subconjunctival space, usually those that supply the conjunctiva or episclera. Trauma is the most common cause, followed by spontaneous idiopathic cases, Valsalva manoeuvres, and several systemic diseases. Although subconjunctival haemorrhages can look alarming, they are rarely an indicator of anything sinister.

Subconjunctival haemorrhages are more common in women than in men when there has been no history of trauma. The annual incidence of non-traumatic subconjunctival haemorrhages is 0.6%, and the risk increases with age as the risk factors are more common in elderly patients. Newborns are also more susceptible. The incidence of both traumatic and non-traumatic subconjunctival haemorrhages is 2.6%.

The most common causes of subconjunctival haemorrhages are trauma and contact lens usage, which are often the sole risk factor in younger patients. Other risk factors include idiopathic causes, Valsalva manoeuvre, hypertension, bleeding disorders, drugs such as aspirin, NSAIDs and anticoagulants, diabetes, arterial disease, and hyperlipidaemia.

Subconjunctival haemorrhages are mostly asymptomatic, but patients may experience mild irritation. The main sign is a flat, red patch on the conjunctiva with well-defined edges and normal conjunctiva surrounding it. Traumatic haemorrhages are most common in the temporal region, with the inferior conjunctiva as the next most commonly affected area. Vision should be normal, including acuity, visual fields, and range of eye movements. On examination, the fundus should be normal.

The diagnosis of a subconjunctival haemorrhage is a clinical one. If there is no obvious traumatic cause, check the patient’s blood pressure. If raised, refer the patient appropriately. If the patient is taking warfarin, check the INR. If raised, refer for appropriate adjustments to the dose to bring the INR back into the target range. Recurrent or spontaneous, bilateral subconjunctival haemorrhages warrant investigations for bleeding disorders or other pathology.

Reassure the patient that subconjunctival haemorrhage is a benign condition that will resolve on its own in 2 to

Managing Migraines: Guidelines and Treatment Options

Migraines can be debilitating and affect a significant portion of the population. To manage migraines, it is important to understand the different treatment options available. According to the National Institute for Health and Care Excellence (NICE) guidelines, acute treatment for migraines involves a combination of an oral triptan and an NSAID or paracetamol. For young people aged 12-17 years, a nasal triptan may be preferred. If these measures are not effective, non-oral preparations of metoclopramide or prochlorperazine may be considered, along with a non-oral NSAID or triptan.

Prophylaxis should be given if patients are experiencing two or more attacks per month. NICE recommends topiramate or propranolol, depending on the patient’s preference, comorbidities, and risk of adverse events. Propranolol is preferred in women of childbearing age as topiramate may be teratogenic and reduce the effectiveness of hormonal contraceptives. Acupuncture and riboflavin may also be effective in reducing migraine frequency and intensity for some people. For women with predictable menstrual migraines, frovatriptan or zolmitriptan may be recommended as a type of mini-prophylaxis.

Specialists may consider other treatment options, such as candesartan or monoclonal antibodies directed against the calcitonin gene-related peptide (CGRP) receptor, like erenumab. However, pizotifen is no longer recommended due to common adverse effects like weight gain and drowsiness. It is important to exercise caution with young patients as acute dystonic reactions may develop. By following these guidelines and considering various treatment options, migraines can be effectively managed.

Explanation of Hypertension and Possible Causes

Hypertension, or high blood pressure, can have various underlying causes. In the case of this patient, their symptoms suggest a rare tumour called phaeochromocytoma, which secretes catecholamines and can lead to malignant hypertension. Hyperaldosteronism and excess cortisol production (Cushing’s syndrome) are other possible causes of hypertension, but they do not explain the patient’s symptoms. Abnormalities in renin, which regulates blood pressure, can also contribute to hypertension. Hyperthyroidism could explain most of the patient’s symptoms, but it is less likely to cause severe hypertension or headaches. Therefore, further investigation is needed to confirm the diagnosis and determine the appropriate treatment.

Sildenafil, also known as Viagra, is typically used to treat erectile dysfunction in adults. However, it can also be used to treat pulmonary hypertension in neonates. The appropriate method for calming a distressed neonate depends on the underlying cause, which is often related to respiratory distress or pain. Gaviscon and ranitidine are sometimes used to treat gastro-oesophageal reflux, although this is not an approved use. Caffeine is sometimes used to help wean a neonate off a ventilator.

Understanding Phosphodiesterase Type V Inhibitors

Phosphodiesterase type V (PDE5) inhibitors are medications used to treat erectile dysfunction and pulmonary hypertension. These drugs work by increasing the levels of cGMP, which leads to the relaxation of smooth muscles in the blood vessels supplying the corpus cavernosum. The most well-known PDE5 inhibitor is sildenafil, also known as Viagra, which was the first drug of its kind. It is a short-acting medication that is usually taken one hour before sexual activity.

Other PDE5 inhibitors include tadalafil (Cialis) and vardenafil (Levitra). Tadalafil is longer-acting than sildenafil and can be taken on a regular basis, while vardenafil has a similar duration of action to sildenafil. However, these drugs are not suitable for everyone. Patients taking nitrates or related drugs, those with hypotension, and those who have had a recent stroke or myocardial infarction should not take PDE5 inhibitors.

Like all medications, PDE5 inhibitors can cause side effects. These may include visual disturbances, blue discolouration, non-arteritic anterior ischaemic neuropathy, nasal congestion, flushing, gastrointestinal side-effects, headache, and priapism. It is important to speak to a healthcare professional before taking any medication to ensure that it is safe and appropriate for you.

Overall, PDE5 inhibitors are an effective treatment for erectile dysfunction and pulmonary hypertension. However, they should only be used under the guidance of a healthcare professional and with careful consideration of the potential risks and benefits.

Prostate Cancer and Ethnicity: Understanding the Differences

Prostate cancer is a disease that affects men of all ethnicities, but the prevalence and mortality rates vary significantly among different racial groups. African-Caribbean men have the highest incidence and mortality rates, while Chinese and Indian men tend to have lower rates. White men have an intermediate risk, with the highest rates in certain regions. However, the role of genetics versus environmental factors is still unclear, and access to healthcare and socioeconomic status may also play a role. Understanding these differences is crucial for improving prevention, diagnosis, and treatment of prostate cancer in all populations.

Endocrine Disorders: Addison’s Disease, Cushing Syndrome, and Conn Syndrome

Addison’s Disease:
Addison’s disease, or primary hypoadrenalism, is a condition characterized by chronic adrenal insufficiency. It is most commonly caused by autoimmune destruction of the adrenals in the UK, while tuberculosis is the most common cause worldwide. Other causes include long-term exogenous steroid use, cancer, or hemorrhage damage. Symptoms develop gradually, but patients can present in Addisonian crisis if there is a sudden deterioration in adrenal function or a physiological stress that the residual adrenal function cannot cope with. Treatment is with long-term replacement of corticosteroids and aldosterone.

Cushing Syndrome:
Cushing syndrome is a result of excess corticosteroid. It can be caused by exogenous steroids, primary hyperadrenalism, or secondary hyperadrenalism. Signs and symptoms include weight gain with moon facies and buffalo hump, hypertension, hyperglycemia, mood changes, hirsutism, baldness, and sleep disturbance.

Conn Syndrome:
Conn syndrome, also known as primary hyperaldosteronism, is caused most commonly by adrenal hyperplasia or adenomas. It results in excess aldosterone release, causing difficult-to-treat hypertension, hypernatremia, and hypokalemia.

Other Disorders:
Hypoglycemia occurs in insulinoma, but the other features are absent. Peutz-Jeghers syndrome is an autosomal dominant condition characterized by perioral freckling and small bowel polyps, which may present with vomiting secondary to intussusception from the small polyps but does not explain the hypoglycemia.

CA 19-9 and Pancreatic Cancer

Understanding Tumour Markers

Tumour markers are substances that can be found in the blood, urine, or tissues of people with cancer. They are often used to help diagnose and monitor cancer, as well as to determine the effectiveness of treatment. Tumour markers can be divided into different categories, including monoclonal antibodies against carbohydrate or glycoprotein tumour antigens, tumour antigens, enzymes, and hormones.

Monoclonal antibodies are used to target specific tumour antigens, which are proteins or other molecules that are found on the surface of cancer cells. Some common tumour markers include CA 125 for ovarian cancer, CA 19-9 for pancreatic cancer, and CA 15-3 for breast cancer. However, it is important to note that tumour markers usually have a low specificity, meaning that they can also be found in people without cancer.

Tumour antigens are proteins that are produced by cancer cells and can be detected in the blood or tissues of people with cancer. Some examples of tumour antigens include prostate specific antigen (PSA) for prostatic carcinoma, alpha-feto protein (AFP) for hepatocellular carcinoma and teratoma, and carcinoembryonic antigen (CEA) for colorectal cancer.

Enzymes and hormones can also be used as tumour markers. For example, alkaline phosphatase and neurone specific enolase are enzymes that can be elevated in people with cancer, while hormones such as calcitonin and ADH can be used to detect certain types of cancer.

In summary, tumour markers are an important tool in the diagnosis and monitoring of cancer. However, they should be used in conjunction with other diagnostic tests and imaging studies, as they are not always specific to cancer and can also be elevated in people without cancer.